| 02:40a | Chugai Pharmaceutical : Full Year Results (Jan-Dec 2022) | PU |
| 02/01 | Chugai Pharmaceutical : Hemlibra Approved by the European Commission to Treat People with .. | PU |
| 01/17 | Japan's Nikkei rises as investors brace for BOJ decision | RE |
| 2022 | Japan's Nikkei ends flat, posts first annual loss in 4 years | RE |
| 2022 | Japanese shares track Wall Street rise, caution ahead of holiday caps gains | RE |
| 2022 | CHUGAI PHARMACEUTICAL CO., LTD : Ex-dividend day for fina.. | FA |
| 2022 | Chugai Pharmaceutical : The Launch of Chugai's New TV Commercial Featuring Tori Matsuzaka .. | PU |
| 2022 | CHMP Recommends Expansion of EU Label for Hemlibra to Include People with Moderate Hemo.. | AQ |
| 2022 | CHMP recommends expansion of EU label for Hemlibra to include people with moderate haem.. | AQ |
| 2022 | Interim data from phase III study presented at ASH 2022 show Hemlibra achieved meaningf.. | AQ |
| 2022 | Chugai and Towa Launch Edirol Tablet for Osteoporosis Treatment | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Transfer and Future Marketing of Osteoporosis Agent B.. | AQ |
| 2022 | Taisho Pharmaceutical Holdings Co., Ltd. (TSE:4581).. | CI |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Organizational and Personnel Changes | AQ |
| 2022 | Chugai Pharmaceutical : Organizational and Personnel Changes | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Contribution of Para-transit Vehicles to Welfare Serv.. | AQ |
| 2022 | Chugai Pharmaceutical and IBM Japan Initiate Operation of Digital Infrastructure at Uki.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Purchase of Land for Business in Ukima | AQ |
| 2022 | Chugai Pharmaceutical : Purchase of Land for Business in Ukima | PU |
| 2022 | Chugai Announces 2022 3rd Quarter Results | AQ |
| 2022 | Chugai Pharmaceutical's FY22 Nine-month Net Income Surges 33% on Significant Jump in Sa.. | MT |
| 2022 | Nikkei 225 Up 1% as Earnings Season Gets Underway | MT |
| 2022 | Japanese stocks rise as Nidec's strong results boost earnings optimism | RE |
| 2022 | Japanese stocks rise on boost from Nidec on strong earnings | RE |
| 2022 | Global markets live: Tesla, Goldman Sachs, Mattel, Apple, Shell... | |
| 2022 | Chugai Pharmaceutical : Supplementary Materials | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. Provides Dividend Guidance for the Year Ending December.. | CI |
| 2022 | Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year o.. | CI |
| 2022 | Construction of Chugai's New Research Center 'Chugai Life Science Park Yokohama' Reache.. | AQ |
| 2022 | Chugai Pharmaceutical : 3Q Results (Jan-Sep 2022) | PU |
| 2022 | Chugai Pharmaceutical : Construction of Chugai's New Research Center “Chugai Life Sc.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Relief Efforts Support for Season's Fifteenth Typhoon | AQ |
| 2022 | Chugai Pharmaceutical : Files New Drug Application in Japan for Fixed-Dose Subcutaneous Co.. | PU |
| 2022 | Japan's Nikkei tracks Wall Street higher as Treasury yields fall | RE |
| 2022 | Japan's Nikkei ends week on a high in hawkish climate | RE |
| 2022 | Japanese stocks gain as investors digest cenbank decisions | RE |
| 2022 | Chugai Pharmaceutical : Summary | PU |
| 2022 | Roche's Japanese Unit Obtains Approval For Anticancer Medication | MT |
| 2022 | Chugai Pharmaceutical : Obtains Regulatory Approval for POLIVY for Additional Indication o.. | PU |
| 2022 | Chugai Pharmaceutical : and Noile-Immune Biotech Enter into a License Agreement for Noile-.. | PU |
| 2022 | Chugai Pharmaceutical : Obtains Regulatory Approval for Osteoporosis Treatment Edirol Tabl.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Anti-C5 Recycling Antibody Crovalimab Obtains Priorit.. | AQ |
| 2022 | Roche's Rare Blood Disease Drug Wins Priority Review Tag In China | MT |
| 2022 | Chugai Pharmaceutical : Anti-C5 Recycling Antibody Crovalimab Obtains Priority Review in C.. | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Notice of the Settlement of Patent Infringement Litig.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Maruho Launched in Japan the Anti-IL-31 Receptor a Hu.. | AQ |
| 2022 | Chugai Pharmaceutical : Notice of the Settlement of Patent Infringement Litigation in the .. | PU |
| 2022 | Roche's Chugai Unit Launches Skin Disease Drug in Japan | MT |
| 2022 | Chugai Pharmaceutical : Maruho Launched in Japan the Anti-IL-31 Receptor A Humanized Monoc.. | PU |
| 2022 | Nikkei 225 Up 0.2% Ahead of Federal Reserve Announcement | MT |
| 2022 | Nikkei inches lower while traders wait on Fed | RE |
| 2022 | Chugai Pharmaceutical : Script (including Q&A) | PU |
| 2022 | Chugai Pharmaceutical's Net Income Soars 73% on Higher Sales of New Products | MT |
| 2022 | Chugai Pharmaceutical and Swiss Parent Tweak Basic Alliance Agreement Post Prime Market.. | MT |
| 2022 | Chugai Pharmaceutical Co., Ltd. - F. Hoffmann-La Roche Announces Half Year Results 2022 | AQ |
| 2022 | Chugai Pharmaceutical : Supplementary Materials for Consolidated Financial Results for the.. | PU |
| 2022 | Chugai Pharmaceutical : CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited)(for the sec.. | PU |
| 2022 | Chugai Pharmaceutical : Announces 2022 Half Year Results | PU |
| 2022 | Chugai Pharmaceutical : Personnel Changes | PU |
| 2022 | Chugai Pharmaceutical : Partial Revision of the Basic Alliance Agreement with Roche | PU |
| 2022 | Chugai Pharmaceutical : Supplementary Materials | PU |
| 2022 | Chugai Pharmaceutical : 2Q Results (Jan-Jun 2022) | PU |
| 2022 | Chugai Pharmaceutical Co., Ltd. Announces Dividend Guidance for the Year Ending Decembe.. | CI |
| 2022 | Chugai Pharmaceutical Co., Ltd. Announces Dividend for the Second Quarter Ending June 3.. | CI |
| 2022 | Chugai Pharmaceutical Co., Ltd. Provides Consolidated Earnings Guidance for Full Year o.. | CI |
| 2022 | Chugai Pharmaceutical Co., Ltd. Announces Partial Revision of the Basic Alliance Agreem.. | CI |
| 2022 | Dolphin Unit Closes $8 Million Purchase of High Reserve F&B in Cash-Stock Deal; Dolphin.. | MT |
| 2022 | Chugai Pharmaceutical : F. Hoffmann-La Roche Announces Half Year Results 2022 | PU |
| 2022 | Chugai Pharmaceutical : Conference on FY2022.12 2Q Financial Results | PU |
| 2022 | Chugai's Osteoporosis Agent Edirol Launched in China | AQ |
| 2022 | Chugai Pharmaceutical Continues to be Listed for All ESG Indices Selected by GPIF | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - Primary Analysis of Japanese Phase III Clinical Trial.. | AQ |
| 2022 | Chugai Pharmaceutical Co., Ltd. - New Data from Phase III HAVEN 6 Study Reinforce Favor.. | AQ |
| 2022 | New data from phase III HAVEN 6 study reinforce favourable safety and efficacy profile .. | AQ |
| 2022 | Chugai Pharmaceutical : Primary Analysis of Japanese Phase III Clinical Trial of Hemlibra .. | PU |
Google
Twitter
Facebook
Apple
English (UK)
English (Canada)
Deutsch (Deutschland)
Deutsch (Schweiz)
Español
Français (France)
Italiano
Nederlands (Nederland)
Nederlands (België)
Report
